Related by context. All words. (Click for frequent words.) 81 albiglutide currently 76 Syncria ® 73 Meets Primary Endpoint 73 albiglutide 72 Initiates Clinical Trial 72 Transdermal Patch 72 Completes Patient Enrollment 72 dyslipidemia hypertension diabetes 71 Personalized Immunotherapy 71 Initiates Enrollment 71 Lupus Nephritis 71 induced macular edema 71 Combination REOLYSIN R 71 pralatrexate injection folate analogue 71 Adjuvant Treatment 70 Granted Orphan Drug 70 Advanced Melanoma 70 Initiates Phase II 70 Phase 2b Clinical Trial 70 dependent kinase inhibitor 70 Frozen Shoulder syndrome Adhesive 70 FOLOTYN ® 70 formerly LymphoStat B 70 toenail onychomycosis 70 ALN HPN 70 hyperphenylalaninemia HPA due 70 Achieves Primary Endpoint 70 Pooled Analysis 69 R Saizen R 69 LymphoStat B belimumab 69 MKC# MT 69 Clinical Trial Results 69 Trial Evaluating 69 Study Evaluating 69 R lenalidomide 69 Investigational Treatment 69 Begins Dosing 69 Panzem R 69 Files IND 69 Hsp# Inhibitor 69 CYT# potent vascular disrupting 69 including eniluracil ADH 69 retinal vein occlusion induced 69 First Patient Enrolled 69 Phase 2a Trial 69 Empatic TM 69 Receives Orphan Drug Designation 69 Drug Candidate 69 Investigational Compound 69 Novel Oral 69 Patients Treated With 69 Acute Exacerbations 69 chronic thromboembolic pulmonary 69 delivers fluocinolone acetonide FA 69 personalized cellular immunotherapy 69 Tezampanel 68 Slow Progression 68 Amgen Neulasta R 68 TRANSDUR ® 68 By JENNIFER LEARN 68 essential thrombocythemia ET 68 Completes Enrollment 68 sorafenib tablets 68 CTAP# 68 Solazed TM 68 Prolongs Survival 68 Phase 2b Trial 68 novel VDA molecule 68 Shows Promise Against 68 Phase 2a Clinical Trial 68 candesartan cilexetil 68 myocardial infarction ventricular fibrillation 68 Subgroup Analysis 68 BENLYSTA ® 68 Liprotamase 68 Initiate Phase 68 Hormone Refractory Prostate Cancer 68 Phase III Trial 68 methylnaltrexone bromide 68 diarrhea predominant irritable 68 Submits NDA 68 disease GERD 68 Vitrasert R 68 Safinamide 68 investigational pharmacologically unique 68 Aflibercept 68 non splenectomized 68 J Am Coll 68 Hepatocellular Carcinoma 68 Patient Enrollment 68 TNF Tumor Necrosis Factor 68 orally inhaled migraine 68 rasagiline tablets 68 Benign Prostatic Hyperplasia 68 MKC# 68 targeting Inflammatory Bowel 68 CTAP# Capsules 68 Initiates Phase III 68 Dose Ranging Study 68 Oral Fingolimod 68 BENLYSTA TM 68 acetonide FA 68 modified glutathione analog 68 Severe Sepsis 68 thetreatment 68 FUSILEV ® 68 catheter occlusion 68 CCX# B 67 Phase IIb Clinical Trial 67 refractory chronic lymphocytic 67 delta gamma agonist 67 Lowers Risk 67 NASH Huntington 67 Pegloticase 67 interferon beta 1a infertility 67 Heterozygous Familial Hypercholesterolemia 67 ELADUR ™ 67 Pivotal Phase III 67 FDA APPROVES 67 evaluating picoplatin 67 AVAPRO 67 INSPIRE Trial Phase III 67 bone marrow reticulin deposition 67 Demonstrates Significant 67 lexidronam injection 67 Controlled Trial 67 Relapsing Multiple Sclerosis 67 Presents Positive 67 Randomized Double blind 67 treat chronic sinusitis 67 Eluting Stent 67 Renal Cell Carcinoma 67 JAK2 Inhibitor 67 neuropathic pain spasticity 67 SPRYCEL ® 67 metastatic castration resistant 67 psoriasis rheumatoid arthritis 67 Tramiprosate ALZHEMED TM 67 rheumatoid arthritis inflammatory bowel 67 Inhalation Aerosol 67 HER2 Positive Breast Cancer 67 Eculizumab 67 non alcoholic steatohepatitis 67 Naive Patients 67 oral proteasome inhibitor 67 CYP#A# CYP#D# 67 Patients Receiving 67 Phase IIb Trial 67 MAGE A3 ASCI 67 Elagolix 67 novel orally inhaled 67 Crit Rev 67 Cerebril TM 67 Demonstrates Efficacy 67 Myelodysplastic Syndrome MDS 67 induced mucositis 67 ALN PCS 67 Crofelemer budesonide foam 67 Preclinical Models 67 Archexin 67 Chronic Hepatitis C 67 TELINTRA R 67 Pivotal Trial 67 FDA Approvals 67 Receives Orphan Drug 67 oral picoplatin 67 gastrin analogue TT 67 Non Alcoholic Steatohepatitis 67 GATTEX TM 67 Node Positive 67 dihydrochloride Tablets 67 PRN FDA Approves 67 Shows Statistically Significant 67 oncolytic virus therapies 67 platform HDL Mimetic 67 AVONEX ® 66 familial amyloidotic polyneuropathy FAP 66 R sorafenib tablets 66 Investigational Oral 66 erythematosus 66 Hyperlipidemia 66 Nonalcoholic Steatohepatitis 66 See CLINICAL PHARMACOLOGY 66 refractory gout 66 pioglitazone HCl 66 ® lenalidomide 66 Clinical Trial Evaluating 66 Ozarelix 66 Teva Provides Update 66 monoclonal antibody conjugated 66 mGluR2 positive 66 PEGINTRON TM 66 Metastatic Melanoma 66 ISTODAX ® 66 Tyrosine Kinase Inhibitor 66 INCB# [003] 66 Initiates Phase 2b 66 metastatic pancreatic 66 sodium thiosulfate STS 66 Slows Progression 66 Initiate Clinical Trial 66 Diabetic Nephropathy 66 Demonstrates Positive 66 BCG refractory carcinoma 66 dasatinib Sprycel ® 66 erosive gastritis 66 sodium glucose cotransporter 66 PNP inhibitor 66 NDA Submission 66 beta 1a 66 Successfully Completes Phase 66 Levels Linked 66 IL# PE#QQR 66 Xeloda ® 66 Central Retinal Vein 66 RNAi Therapeutic 66 Randomized Phase 66 Albugon 66 Previously Treated 66 Initiated Phase 66 AFREZZA TM 66 Empatic ™ 66 Interferon Beta 66 Oral Calcitonin 66 Is Well Tolerated 66 TRANSDUR ™ 66 Muraglitazar 66 metastatic colorectal 66 Improved Survival 66 Romidepsin 66 Shows Efficacy 66 Zorbtive TM 66 GW# [003] 66 resistant hormone refractory 66 Thiazolidinediones 66 Drug Shows Promise 66 phase III isavuconazole 66 Pivotal Phase 66 oral antidiabetic medication 66 Peginterferon alfa 2b 66 Nonalcoholic Fatty Liver Disease 66 IMiDs ® 66 Initiates Clinical 66 Vildagliptin 66 Antitumor Activity 66 PLX STROKE targeting 66 Bucindolol 66 Adjunctive Therapy 66 metaglidasen 66 AFREZZA ™ 66 Complicated Skin 66 Daclizumab 66 Phase III Clinical Trial 66 II Clinical Trial 66 Fondaparinux 66 kidney urologic 66 individualized cellular immunotherapy 66 Hypertensive Patients 66 2 methoxyestradiol 66 pentadentate logo R 66 molecular imaging radiopharmaceutical 66 evaluating mipomersen 66 Long Term Efficacy 66 Improves Outcomes 66 Vicriviroc 66 Kuvan R 66 Commences Phase 66 Platinol ® 66 Anti Tumor 66 cause cardiac channelopathies 66 MTP inhibitor 66 oral dual endothelin 66 Cleviprex TM clevidipine 66 generation DACH Platinum 66 Bayer HealthCare Onyx Pharmaceuticals 66 Predict Risk 66 bladder ovarian 66 hyperplasia BPH 66 vaginal candidiasis 66 XL# anticancer compounds 66 Receives Fast Track 66 VEGFR2 inhibitor 66 Primary Hypercholesterolemia 66 oral prodrug 66 Demonstrated Significant 66 Testosterone MDTS R 66 vitreoretinal disorders 66 TKB# 66 Non Alcoholic Fatty 66 hypoxia activated prodrug 65 IN PATIENTS WITH 65 Single Dose 65 MKC# MKC# PP 65 Inhalation Solution 65 systemic anaplastic large 65 LymphoStat B TM 65 Shows Promising 65 FOLFOX6 chemotherapy regimen 65 Abstract Accepted 65 Pivotal Study 65 Namenda ® 65 proliferator activated receptor 65 Phase III Pivotal 65 6R BH4 65 Genes Predict 65 Xcytrin R 65 Deforolimus 65 lintuzumab SGN 65 Glufosfamide 65 Presents Preclinical 65 myelodysplastic myeloproliferative diseases 65 Immunotherapeutic 65 Lymphocytic 65 Cetrorelix 65 Refractory Hodgkin Lymphoma 65 Phase #b/#a clinical 65 Treatment Shows Promise 65 forodesine 65 orally administered inhibitor 65 SUPPRELIN R LA 65 Lubiprostone 65 Trodusquemine MSI 65 Mylan Receives Approval 65 Atypical Hemolytic Uremic Syndrome 65 oral ghrelin agonist 65 Vaccine Adjuvant 65 RELOVAIR ™ 65 product platforms AZX# 65 mild vasodilator 65 Hypercholesterolemia 65 approved incretin mimetic 65 Presents Preclinical Data 65 Ranolazine 65 MOVIPREP R 65 LENALIDOMIDE 65 R roscovitine CDK cyclin 65 MEK Inhibitor 65 dopamine D2 65 VICTOR E3 65 Malignant Melanoma 65 purpura ITP 65 Asthma COPD 65 Cutaneous T 65 Secondary Hyperparathyroidism 65 hormone refractory metastatic prostate 65 VIVITROL ® 65 Efficacy Trial 65 Pafuramidine 65 Serostim ® 65 oral nucleoside analogue 65 Seliciclib CYC# 65 M# rationally 65 Ovitrelle R Serostim 65 Survival Benefit 65 First Patient Dosed 65 Patients Undergoing 65 NICE Recommends 65 IV Busulfex 65 Drug Fails 65 Improves Survival 65 Boniva ibandronate 65 Syncria albiglutide 65 Myocet 65 Initiates Clinical Trials 65 Preclinical Study 65 candidates Azedra TM 65 topically applied SEPA 65 Intervention Effectiveness 65 allosteric modulator NAM 65 Artery Disease 65 Drug Prevents 65 Initiates Dosing 65 Demonstrates Sustained 65 Prodarsan R 65 Silodosin 65 PANVAC VF 65 ORENCIA R 65 Submits Biologics License Application 65 brand ciclesonide HFA 65 metastatic renal 65 ACTEMRA TM 65 Glatiramer Acetate 65 FDA Okays 65 metastatic malignant 65 carcinoma mCRC 65 tumor activated prodrug 65 Diabetic Macular Edema DME 65 PEGylated interferon beta 1a 65 PEGylated anti 65 AVASTIN 65 NB S# strontium malonate 65 Phase IIa Clinical Trial 65 CIMZIA TM certolizumab pegol 65 Hypertriglyceridemia 65 Trandolapril 65 Receives Approvable Letter 65 Mg Usa 65 Tiotropium 65 Heart Failure Patients 65 PF # [002] 65 FDA Accepts 65 Preclinical Efficacy 65 DIRECT Trial 65 vapreotide acetate 65 Bronchopulmonary Dysplasia 65 SinuNase TM 65 GERD migraine headaches 65 PEGylated Fab fragment 65 ThermoDox R 65 Nicotine Vaccine 65 Acute Heart Failure 65 primary hypercholesterolemia 65 human C1 inhibitor 65 including thyroiditis RA 65 Atherosclerotic 65 neuropathic pain metabolic diseases 65 endocrinology gastroenterology 65 Dose Escalation 65 DG# compounds targeting 65 Predict Response 65 non nucleoside inhibitor 64 oral beclomethasone dipropionate 64 Mg Uk 64 Relapsed Refractory 64 Initiate Phase III 64 Clolar ® 64 Aryplase 64 HCV Protease Inhibitor 64 Familial Adenomatous Polyposis FAP 64 ARRY # 64 relapsed MM 64 tiapamil 64 Tesetaxel 64 octreotide implant 64 compound INCB# 64 thiazolidinedione TZD 64 Inflammatory Markers 64 AAG geldanamycin analog 64 Combo Therapy 64 ® pioglitazone HCl 64 Resistant Hypertension 64 Rheumatoid Arthritis Drug 64 Myeloma Patients 64 erlotinib Tarceva ® 64 Treated Patients 64 Interferon beta 1a 64 Belimumab 64 Virus Linked 64 Solazed ™ 64 Renal Cancer 64 Am J Obstet 64 Capsulitis 64 Bazedoxifene 64 Proc Am Soc 64 alpha1 antitrypsin deficiency 64 chronic eosinophilic leukemia 64 Prednisone Against Refractory 64 Advanced Renal Cell 64 dyskinesia PD LID 64 GVAX ® 64 complement inhibitor eculizumab 64 RhuDex ® 64 Successfully Treated 64 ALN TTR 64 ATRA IV 64 inflammatory autoimmune diseases 64 dextromethorphan quinidine 64 Reminyl galantamine 64 Aviptadil 64 diabetes hyperlipidemia 64 Phase Ib Clinical Trial 64 Denufosol 64 itraconazole Sporanox 64 PENTASA 64 Clinical Outcome 64 Newly Diagnosed Multiple Myeloma 64 Rotavirus Vaccine 64 ILUVIEN ® 64 pain palliation 64 somatostatin analog 64 Metastatic Prostate Cancer 64 mecarbil 64 OMNARIS HFA 64 Multiple Ascending Dose 64 Antiplatelet 64 Meta Analysis 64 selective modulator 64 Relapsed Multiple Myeloma 64 Chronic Bronchitis 64 dyslipidemia abnormal 64 chronic myeloid 64 Amgen Neulasta ® 64 systemic lupus erythematosus psoriasis 64 Eur J 64 Zemiva TM 64 Evoltra ® 64 J Am Acad 64 #-# Full Text 64 Oral Insulin 64 gastrointestinal mucositis 64 Veronate R 64 cMET 64 HQK 64 familial hypercholesterolemia FH 64 cell carcinoma RCC 64 alvespimycin 64 herpetic keratitis 64 Therapy Improves 64 mGluR5 negative 64 lamotrigine Lamictal 64 relapsed leukemia 64 Combination Treatment 64 castrate resistant prostate cancer 64 BARACLUDE ® 64 Disease Modifying 64 Entereg R 64 Febuxostat 64 Microplasmin 64 allosteric modulator PAM 64 recurrent metastatic ovarian cancer 64 aripiprazole Abilify 64 systemic juvenile idiopathic 64 Systemic Sclerosis 64 overactive bladder syndrome 64 Successfully Treats 64 aplastic anemia AA 64 infectious diseases autoimmune diseases 64 azilsartan medoxomil 64 RhuDex 64 Allergic Rhinitis 64 RNAi therapeutic targeting PCSK9 64 SGPT 64 Randomized Study 64 ALVESCO ® 64 Vascular Disrupting Agent 64 acute mania 64 PROVENGE ® 64 miconazole Lauriad ® 64 Associated Adipose Redistribution 64 JAK Inhibitor 64 Intravenous CP 64 dual PPAR peroxisome 64 5 fluorouracil leucovorin 64 mitoxantrone plus 64 SNT-MC#/idebenone 64 INS# [001] 64 Ridaforolimus 64 Pirfenidone 64 sapropterin dihydrochloride Tablets 64 Ceflatonin R 64 Cardiovascular Outcomes 64 Chemotherapy induced 64 radiation enteritis 64 peripheral arterial occlusive disease 64 5 FU leucovorin 64 Perflubutane Polymer Microspheres 64 IND Application 64 INTEGRILIN ® 64 trial evaluating PRX# 64 Erythropoietic therapies may 64 Prospective Randomized 64 metastatic castrate resistant 64 MyVax ® 64 Recombinant Human 64 dyslipidaemia 64 Endometrial Cancer 64 developing Bicifadine serotonin 64 Medoxomil 64 Sapacitabine 64 investigational oral inhibitor 64 Cardiotoxicity 64 PHX# 64 novel antimitotic agent 64 Hydrochlorothiazide Tablets 64 NuroPro R 64 Treating Chronic 64 lupus erythematosus 64 metastatic hormone refractory 64 either acutely decompensated 64 Ribavirin causes 64 Panzem ® 64 Darapladib 64 Subtypes 64 NU# direct 64 Squalamine 64 Humanized Anti 64 Phase Ib IIa 64 polycythemia vera essential thrombocythemia 64 Postmenopausal Women 64 Soft Tissue Sarcoma 64 Announces Poster Presentations 64 Parathyroid Hormone 64 CINQUIL 64 Kinase Inhibitor 64 refractory cutaneous T 64 Systemic Lupus Erythematosus SLE 64 Preclinical Data 64 Invasive Breast Cancer 64 Clinical Trial Data 64 R pioglitazone HCl 64 3 registrational trial 64 Novel Treatments 64 Acetate Rectal Suppositories 64 hyperlipemia 64 immuno inflammatory diseases 64 Darinaparsin 64 imatinib Gleevec ® 64 Knee Osteoarthritis 64 Study Shows Promise 64 Novel Compound 64 sirtuin inhibitor program 64 Sustained Efficacy 64 Diabetic Neuropathy 64 IIa Clinical Trial 64 Confirmatory Phase 64 Plaque Psoriasis 64 myelofibrosis polycythemia vera 64 stage IIIb IV 64 LUNESTA ® 64 Angiotensin Converting Enzyme 63 Oracea TM 63 Relapsing Remitting Multiple Sclerosis 63 Migraine Drug 63 Randomized Phase II 63 schizophrenia CIAS 63 Reports Preclinical Data 63 NSAID associated 63 Elotuzumab 63 Mycophenolate Mofetil 63 Platelet Inhibition 63 Atopic Dermatitis 63 Novel Therapeutic 63 homozygous familial hypercholesterolemia 63 Paraplatin ® 63 Neovascular Age Related Macular 63 CCR5 mAb 63 virus HCV protease inhibitor 63 Aliskiren 63 pan HDAC inhibitor 63 Study Showed 63 HER2 Positive 63 EDEMA3 63 Hyperphosphatemia 63 antibody MAb 63 Sevelamer 63 ularitide 63 novel nucleoside analog 63 Rheumatoid Arthritis RA 63 Cancer Incidence Mortality 63 antiangiogenesis therapies 63 Nonalcoholic fatty liver 63 Antigen Specific 63 Leukemias 63 STRIDE PD 63 advanced hepatocellular carcinoma 63 syndrome gastroesophageal reflux 63 neovascular form 63 Navelbine ® 63 metastatic GIST 63 Aurora Kinase 63 arthritis PsA 63 Aceon 63 Phase 1b clinical trials 63 Sudhir Agrawal D.Phil 63 migraine headaches neuropathic pain 63 interferon gamma 1b 63 Luramist TM 63 Vytorin combines 63 atypical Hemolytic Uremic Syndrome 63 Sangamo BioSciences Announces 63 Cystatin C 63 Commence Phase 63 humanized interleukin 6 63 Intravitreal 63 THAT ARE DIFFICULT TO 63 sunitinib Sutent ® 63 initiated Phase Ib 63 undergoing elective percutaneous 63 epoetin zeta 63 Cholesterol Lowering Drug 63 constipation OIC 63 Placebo Controlled Study 63 IMiDs R 63 hypercholesterolemic patients 63 Metastatic Colorectal Cancer 63 hereditary emphysema 63 Pivotal Phase II 63 metastatic gastric 63 EVIZON TM 63 Pimavanserin 63 cardiometabolic diseases 63 Refractory Angina 63 evaluating tivozanib 63 Degarelix 63 gefitinib Iressa 63 acyclovir Lauriad R 63 PDX pralatrexate 63 Maven Semantic 63 Inhaled Corticosteroids 63 Telik Announces 63 Tigecycline 63 drug pipeline TAFA# 63 non cirrhotic portal 63 Develop Novel 63 Breast Cancer Recurrence 63 Chronic Heart Failure 63 PROSTVAC VF 63 Peginterferon 63 substantially excreted 63 NYHA Class II 63 INTEGRILIN R eptifibatide Injection 63 QNEXA ® 63 tumors GIST 63 GOUT 63 Brentuximab Vedotin SGN 63 RNAi Therapeutics 63 cutaneous T 63 multicenter Phase III 63 Test Detects 63 Neulasta R 63 diarrhea fatigue asthenia 63 midstage clinical 63 sorafenib Nexavar 63 receiving VELCADE 63 Pulmonary Arterial Hypertension 63 Bipolar Depression 63 Launches Generic Version 63 Custirsen 63 HMG CoA reductase inhibitors 63 chronic myocardial ischemia 63 Previously Untreated 63 BENICAR HCT 63 highly selective inhibitor 63 etanercept Enbrel 63 Stage IIB 63 selective estrogen receptor modulator 63 TRO# 63 COLAZAL R 63 temsirolimus Torisel 63 Endocrinol 63 occlusion PAO 63 Warfarin Coumadin 63 Overactive Bladder 63 Temsirolimus 63 bevacizumab Avastin ® 63 plus prednisone 63 Chronic Renal Failure 63 Systemic lupus erythematosus SLE 63 prokinetic agent 63 severe hypercholesterolemia 63 Varespladib 63 Observational Study 63 Treatment Resistant 63 See WARNINGS 63 Tasimelteon 63 Rheumatoid Arthritis Patients 63 cardio metabolic diseases 63 Fibrillex TM 63 elevated LDL cholesterol 63 sunitinib Sutent 63 Omacetaxine 63 worsening thrombocytopenia 63 Ostarine ™ 63 R#/MEM 63 thalidomide Thalomid 63 Gastric Cancer 63 neovascular diseases 63 Factor Receptor 63 TBC# 63 evaluating bafetinib 63 Castration Resistant Prostate Cancer 63 Myelodysplastic Syndromes 63 Respiratory Distress 63 Completes Dosing 63 ZALBIN 63 Showed Significant 63 secondary hyperparathyroidism 63 Vidaza ® 63 rusalatide acetate 63 Lenocta TM 63 Drug Combo 63 AEG# 63 topical gel formulation 63 MetroGel 63 Impaired Glucose Tolerance 63 efaproxiral 63 expanded autologous cellular 63 iobenguane 63 RhuDex TM 63 advanced metastatic renal 63 included neutropenia anemia 63 Left Ventricular Hypertrophy 63 AEGR 63 elevated triglyceride levels 63 Dapagliflozin 63 interferon alpha IFN 63 Statistically Significant 63 Controlled Study 63 Infected Patients 63 dasatinib Sprycel 63 Eluting Coronary Stent System 63 Pulmonary Arterial Hypertension PAH 63 MyVax R 63 PARGLUVA 63 mild renal insufficiency 63 Ceflatonin ® 63 Orally Active 63 immunotherapeutic vaccine 63 Bronchiectasis 63 systemic fungal infections 63 Files Investigational 63 TTR amyloidosis 63 ospemifene 63 Gemzar ® 63 demonstrated antitumor activity 63 J Child Adolesc 63 Chronic Sinusitis 63 ORENCIA ® 63 hyaluronidase enzyme 63 baseline serum creatinine 63 Phase III Clinical Trials 63 Limb Ischemia 63 metformin sulfonylurea 63 CVBT #H 63 Ocrelizumab 63 R bortezomib 63 bucindolol hydrochloride 63 Chronic Myeloid Leukemia 63 Telithromycin 63 ergot derivatives 63 Reduces Risk 63 candidate XP# 63 Brain Metastases 63 Diovan Exforge Tekturna Zelnorm 63 CD# CEA 63 AA Amyloidosis 63 Zemiva ™ 63 headache nasopharyngitis 63 Hypoactive Sexual Desire Disorder 63 doxepin HCl 63 oxaliplatin Eloxatin 63 Zarnestra 63 Protease Inhibitor 63 Patients Suffering 63 ST Elevation Myocardial 63 uricase 63 HuMax 63 relapsing remitting MS RRMS 63 CTAP# Injection 63 LHRH receptor positive 63 ® bortezomib 63 alfa 2a 63 Effectively Treats 63 Cardiac Resynchronization 63 cell lymphoma CTCL 63 Improve Survival 63 inhalation powder 63 novel histone deacetylase 63 Azacitidine 63 rosuvastatin Crestor 63 cognitive impairment associated 63 Janus kinase 63 Unfractionated Heparin 63 HGS ETR1 mapatumumab 63 Proven Effective 63 receptor tyrosine kinase inhibitor 63 severe gastroparesis 63 gastrointestinal stromal 63 Gastrointestinal GI 62 Desvenlafaxine Succinate 62 davunetide intranasal AL 62 adalimumab Humira 62 hypokalemia hypomagnesemia 62 Late Breaker 62 R#/MEM # 62 neuropathy sparing 62 Acute Renal Failure 62 Dose Ranging 62 rheumatoid arthritis thrombocytopenia 62 Qutenza TM 62 pharmacogenomic translational research 62 systemic autoimmune 62 Adjuvant Therapy 62 Intravitreal injections 62 Clinical Evaluation 62 Unstable Angina 62 Biomarker Study 62 VALSTAR TM 62 Int J Obes Relat 62 Recurrent Breast Cancer 62 chronically immunosuppressed solid 62 Pazopanib 62 Cognitive Deficits 62 IgG1 monoclonal antibody 62 targeted radiotherapeutic 62 PI3K/Akt pathway inhibitor 62 dutogliptin 62 small molecule thrombopoietin 62 Investigational Drug 62 chronic immune thrombocytopenic 62 Soriatane 62 Antitumor 62 TRIOLEX HE# APOPTONE HE# 62 Telik logo TELINTRA 62 volociximab 62 Unit Dose Budesonide 62 Occlusive Disease 62 hypereosinophilic syndrome 62 Obstructive Pulmonary Disease 62 Trastuzumab DM1 62 Cannabinor 62 SHPT 62 Kosan dependence 62 HBeAg negative 62 Squamous 62 Alzheimer disease cognitive impairment 62 Canvaxin TM 62 #:#-# [023] 62 lipohypertrophy 62 POSIDUR TM ELADUR TM 62 CCR9 antagonist 62 Efficacy Results 62 IMiDs 62 oral dihydropyrimidine dehydrogenase DPD 62 Spectrum Pharmaceuticals Announces 62 Mouse Model 62 Capoten 62 BRILINTA 62 3g dietary fiber 62 Vaccine Candidate 62 Inflammatory Diseases 62 asthma COPD Chronic 62 Onyx Pharmaceuticals Announces 62 J Am Soc 62 Pivotal Clinical Trial 62 TO AVOID PREGNANCY WHILE 62 Videx Videx EC 62 Ophena TM 62 ST Segment Elevation 62 Retisert ® 62 Am J Clin 62 Proves Effective 62 TLK# 62 essential thrombocythemia 62 ziprasidone Geodon 62 human rDNA origin 62 Receives Milestone Payment 62 therefore therapeutically equivalent 62 olmesartan medoxomil hydrochlorothiazide 62 Pravastatin 62 elotuzumab 62 PEGASYS ® 62 Initiates Phase 62 Treatment Reduces 62 Proellex TM 62 LEVADEX TM 62 R abatacept 62 Expanded Indication 62 Randomized Clinical Trials 62 Double Blind Placebo 62 TRACON Pharmaceuticals 62 Phase 1b Clinical Trial 62 PRTX 62 cancer neuroendocrine tumor 62 CD3 monoclonal antibody 62 Mipomersen 62 products MKC# PP 62 sitaxsentan sodium 62 receiving chemoradiation therapy 62 dihydrochloride 62 ANN INTERN MED 62 Anticancer Drug 62 evaluate ZFP Therapeutic 62 IMPDH inhibitor 62 Agonist MABA program 62 huC# DM4 62 Adjunctive 62 Iluvien ® 62 Treatment Naive Patients 62 Epratuzumab 62 Dosa suffers 62 renal failure interstitial lung 62 Generic Version 62 SinuNase ™ 62 progressive dyspnea 62 ara C 62 Proteinuria 62 Diabetic Patients 62 MAb therapy 62 Stomach Cancer 62 HDL Selective Delipidation 62 mertansine 62 Second Pivotal Phase 62 Bayer Nexavar 62 overt nephropathy 62 selective immunoproteasome inhibitor 62 alpha1 antitrypsin AAT deficiency 62 ocular formulation 62 mesylate